Demand For Surgical Heart Valves Projected To Slowly Decline
The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.
You may also be interested in...
The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.
CMR Surgical has grown rapidly since being founded just over eight years ago. However, unlike most other medtech companies, CMR is not selling a ~$30 diagnostic test, or a ~$5,000 pacemaker. It is selling a complex surgical robot, called Versius, with a price tag rumored to be in the seven figures.
Insulin pumps have lagged behind continuous glucose monitors in terms of market penetration due to their cost and the complex regulatory framework that surrounds them. Elizabeth Gasser, chief strategy officer at Tandem Diabetes spoke to Medtech Insight about these challenges and how the company is taking a slightly different approach to pumps.